阿帕替尼配合化疗对晚期非小细胞肺癌患者预后的影响  

Effect of apatinib combined with chemotherapy on prognosis of patients with advanced non-small cell lung cancer

作　　者：陈菊英 王红哲 练晓珊 吴晓哲 CHEN Juying;WANG Hongzhe;LIAN Xiaoshan;WU Xiaozhe(Pharmacy Department,Guangzhou Taihe Cancer Hospital;Oncology Department,Guangzhou Taihe Cancer Hospital,Guangzhou,Guangdong 510030,China)

机构地区：[1]广州泰和肿瘤医院药学部,广东广州510030 [2]广州泰和肿瘤医院肿瘤内科,广东广州510030

出　　处：《大医生》2022年第23期1-4,共4页Doctor

基　　金：广东省医学科学技术研究基金项目(编号:B2022310)。

摘　　要：目的研究阿帕替尼配合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效及对患者预后的影响,为临床提供参考。方法选取2021年3月至2022年3月广州泰和肿瘤医院收治的72例晚期NSCLC患者为研究对象进行回顾性分析。根据治疗方案的不同将其分为观察组和对照组,各36例。观察组患者采用阿帕替尼配合化疗干预,对照组患者行常规化疗。记录疗效和不良反应发生情况,比较两组患者无进展生存期(PFS)和总生存期(OS)。分别在治疗前后检测两组患者免疫功能指标水平。结果观察组患者客观缓解率(ORR)和整体疗效高于对照组(P<0.05);观察组患者PFS和OS比对照组长(均P<0.05)。两组患者治疗期间中性粒细胞减少、高血压、胃肠道反应、骨髓抑制及手足皮肤反应等不良反应严重程度比较,差异均无统计学意义(均P>0.05)。治疗后观察组患者CD3^(+)和CD4^(+)T淋巴细胞百分比高于对照组,CD8^(+)T淋巴细胞百分比低于对照组(P<0.05)。结论阿帕替尼配合化疗治疗晚期NSCLC疗效显著,有助于延长生存时间,且阿帕替尼安全性良好,在晚期NSCLC中具有较高的临床应用价值。Objective To study the clinical efficacy and prognosis of apatinib combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)and to provide reference for clinic.Methods 72 patients with advanced NSCLC admitted in Guangzhou Taihe Cancer Hospital from March 2021 to March 2022 were selected as the research objects,and a retrospective research was carried out.According to the different treatment schemes,they were divided into observation group and control group,with 36 cases in each group.The observation group received apatinib combined with chemotherapy intervention,and the control group received routine chemotherapy.The treatment effect and adverse reactions were recorded.The progression free survival(PFS)and overall survival(OS)were compared between the two groups.The immune function indexes of the two groups were detected before and after treatment.Results The objective remission rate(ORR)and overall efficacy of the observation group were higher than those of the control group(P<0.05).The PFS and OS in the observation group were significantly longer than those in the control group(P<0.05).There were no significant difference in the severity of neutropenia,hypertension,gastrointestinal reactions,bone marrow suppression and hand foot skin reactions between the two groups during treatment(P>0.05).After treatment,the percentages of T lymphocyte of CD3^(+) and CD4^(+) in the patients of observation group were higher than those in the control group,and the percentages of T lymphocyte of CD8^(+) was lower than that in the control group(P<0.05).Conclusion The apatinib combined with chemotherapy is effective in the treatment of advanced NSCLC,which is helpful to prolong the survival time.The apatinib is safe and has high clinical value in advanced NSCLC.

关 键 词：阿帕替尼 化疗 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]